Company Overview of Battelle Memorial Institute, Inc.
Battelle Memorial Institute, Inc. operates as a science and technology company that develops and commercializes technology in the United States. The company develops technology in the areas of energy, health and life sciences, national security and defense, laboratory management, and community and education. It also offers solutions for advanced materials, agrifood, consumer products, economic development, environment, industrial products, medical devices, pharmaceutical and biotechnology, public health, and transportation sectors, as well as manages laboratories for customers. In addition, the company conducts independent safety audits and assessments of train control/signaling systems and ...
505 King Avenue
Columbus, OH 43201-2696
Founded in 1923
Key Executives for Battelle Memorial Institute, Inc.
Chief Executive Officer and President
Chief Financial Officer and Executive Vice President
Senior Vice President of International Partnerships
Senior Vice President of Laboratory Operations and President of Battelle Energy Technology
President of National Security Global Business and General Manager of Battelles National Security Division
Compensation as of Fiscal Year 2014.
Battelle Memorial Institute, Inc. Key Developments
Battelle Memorial Institute Wins $24.07 Million Federal Contract
Dec 10 14
Battelle Memorial Institute, Columbus, Ohio, won a $24,068,603 federal contract from the Environmental Protection Agency's Office of Acquisition Management, Research Triangle Park, North Carolina, for research and development services on Exposure Screening Tools for Accelerated Chemical Prioritization.
Battelle Memorial Institute, Inc. Wins $30 Million Federal Contract
Nov 19 14
Battelle Memorial Institute, Inc. was awarded a federal contract valued at up to $30 million by the U.S. Marine Corps Systems Command, Quantico, Virginia, for technical support services for the Range and Training Area Management Division's range managers Toolkit.
Discovery Laboratories, Inc. Announces Strategic Collaboration with Battelle for AEROSURF Program
Oct 15 14
Discovery Laboratories, Inc. announced that it has entered into a strategic collaboration with Battelle. The parties intend to further develop Discovery Labs' proprietary capillary aerosol generator for use in the planned AEROSURF phase 3 clinical program and, if approved, initial commercialization. The arrangement also reflects the plan to negotiate agreements to provide for the manufacture of phase 3 clinical devices and, if AEROSURF is approved, initial commercial supply. The CAG is currently being used in neonatal intensive care units for the company's AEROSURF phase 2 clinical program for the treatment of respiratory distress syndrome (RDS) in premature infants. Battelle and Discovery Labs generally will share equally in the agreed costs of the device development for the AEROSURF RDS program. In consideration for its investment and expertise, Battelle will receive warrants and future royalties on AEROSURF sales and license sales revenues. Under the terms of the agreement, Battelle and Discovery Labs will co-invest in the development of an AEROSURF phase 3 clinic-ready aerosol device. Upon execution of the agreement, Battelle received two warrants to purchase a total of 1.5 million shares of Discovery Labs' common stock at an exercise price of $5.00 per share, each warrant with a 10-year term. The first warrant to purchase 1 million shares is exercisable only upon successful development of an aerosol device that is ready for a potential AEROSURF phase 3 clinical program. The second warrant to purchase 0.5 million shares will become exercisable only upon meeting the aforementioned milestone by a certain date. In addition, if AEROSURF receives regulatory approval for the treatment of RDS, Battelle will receive a low single-digit royalty on Discovery Labs' AEROSURF commercial revenues, subject to an aggregate cap of $25 million. AEROSURF is a novel investigational combination drug-device product being developed to deliver the company's synthetic KL4 surfactant in aerosolized form via nasal continuous positive airway pressure to premature infants with RDS. AEROSURF could potentially allow for the administration of KL4 surfactant to premature infants without invasive endotracheal intubation, and may enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated. Discovery Labs is developing its proprietary aerosolization drug delivery technologies, including the CAG, to enable efficient delivery of aerosolized KL4 surfactant. The company is currently conducting a phase 2 clinical program for AEROSURF employing the current version of the CAG.
Similar Private Companies By Industry
Recent Private Companies Transactions